Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1991 1
1993 1
1995 2
1996 1
1997 1
1998 1
1999 1
2000 1
2001 2
2002 1
2003 2
2004 1
2006 1
2007 1
2009 1
2010 2
2013 3
2014 1
2015 3
2016 1
2017 1
2019 1
2020 2
2021 3
Text availability
Article attribute
Article type
Publication date

Search Results

33 results
Results by year
Filters applied: . Clear all
Page 1
First-in-Human Trial of the Oral Ataxia Telangiectasia and RAD3-Related (ATR) Inhibitor BAY 1895344 in Patients with Advanced Solid Tumors.
Yap TA, Tan DSP, Terbuch A, Caldwell R, Guo C, Goh BC, Heong V, Haris NRM, Bashir S, Drew Y, Hong DS, Meric-Bernstam F, Wilkinson G, Hreiki J, Wengner AM, Bladt F, Schlicker A, Ludwig M, Zhou Y, Liu L, Bordia S, Plummer R, Lagkadinou E, de Bono JS. Yap TA, et al. Among authors: bladt f. Cancer Discov. 2021 Jan;11(1):80-91. doi: 10.1158/2159-8290.CD-20-0868. Epub 2020 Sep 28. Cancer Discov. 2021. PMID: 32988960 Free article.
First-in-Man Phase I Trial of the Selective MET Inhibitor Tepotinib in Patients with Advanced Solid Tumors.
Falchook GS, Kurzrock R, Amin HM, Xiong W, Fu S, Piha-Paul SA, Janku F, Eskandari G, Catenacci DV, Klevesath M, Bruns R, Stammberger U, Johne A, Bladt F, Friese-Hamim M, Girard P, El Bawab S, Hong DS. Falchook GS, et al. Among authors: bladt f. Clin Cancer Res. 2020 Mar 15;26(6):1237-1246. doi: 10.1158/1078-0432.CCR-19-2860. Epub 2019 Dec 10. Clin Cancer Res. 2020. PMID: 31822497 Free article. Clinical Trial.
Olig3 regulates early cerebellar development.
Lowenstein ED, Rusanova A, Stelzer J, Hernaiz-Llorens M, Schroer AE, Epifanova E, Bladt F, Isik EG, Buchert S, Jia S, Tarabykin V, Hernandez-Miranda LR. Lowenstein ED, et al. Among authors: bladt f. Elife. 2021 Feb 16;10:e64684. doi: 10.7554/eLife.64684. Elife. 2021. PMID: 33591268 Free PMC article.
Nck adaptors are positive regulators of the size and sensitivity of the T-cell repertoire.
Roy E, Togbe D, Holdorf AD, Trubetskoy D, Nabti S, Küblbeck G, Klevenz A, Kopp-Schneider A, Leithäuser F, Möller P, Bladt F, Hämmerling G, Arnold B, Pawson T, Tafuri A. Roy E, et al. Among authors: bladt f. Proc Natl Acad Sci U S A. 2010 Aug 31;107(35):15529-34. doi: 10.1073/pnas.1009743107. Epub 2010 Aug 13. Proc Natl Acad Sci U S A. 2010. PMID: 20709959 Free PMC article.
Thorium-227-Labeled Anti-CD22 Antibody (BAY 1862864) in Relapsed/Refractory CD22-Positive Non-Hodgkin Lymphoma: A First-in-Human, Phase I Study.
Lindén O, Bates AT, Cunningham D, Hindorf C, Larsson E, Cleton A, Pinkert J, Huang F, Bladt F, Hennekes H, Oedegaardstuen LI, Sturm I, McNamara C. Lindén O, et al. Among authors: bladt f. Cancer Biother Radiopharm. 2021 Apr 21. doi: 10.1089/cbr.2020.4653. Online ahead of print. Cancer Biother Radiopharm. 2021. PMID: 33887152
Fine tuning of the threshold of T cell selection by the Nck adapters.
Roy E, Togbe D, Holdorf A, Trubetskoy D, Nabti S, Küblbeck G, Schmitt S, Kopp-Schneider A, Leithäuser F, Möller P, Bladt F, Hämmerling GJ, Arnold B, Pawson T, Tafuri A. Roy E, et al. Among authors: bladt f. J Immunol. 2010 Dec 15;185(12):7518-26. doi: 10.4049/jimmunol.1000008. Epub 2010 Nov 15. J Immunol. 2010. PMID: 21078909 Free article.
33 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page